Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Mar 30, 2006


Title: Methods of Reducing an Immune Response

Number: 20060063733

Filed: Oct. 31, 2005

Inventor: Quiming Chu, Genzyme

"The invention relates to methods of reducing an immune response to a transgene product in a mammal by co-administration of a small-interfering ribonucleic acid molecule that temporarily inhibits or reduces transgene expression, wherein the siRNA is administered in an amount, and for a period of time, sufficient to reduce an immune response to the transgene product when it is expressed at therapeutic levels," the patent application's abstract states. "The … invention further relates to methods of administering siRNAs to a mammal to reduce an immune response to an immunogenic protein, such as an enzyme used in enzyme replacement therapy."

Title: In Vivo Inhibition of Hepatitis B Virus

Number: 20060063731

Filed: Sept. 26, 2005

Lead Inventor: David Lewis, Mirus

According to the patent application's abstract, the invention involves a process to "deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs," the abstract states.

Title: MicroRNA Vectors

Number: 20060063174

Filed: June 21, 2005

Lead Inventor: David Loyd Turner, University of Michigan

The invention "relates to gene silencing, and in particular to compositions of microRNA sequences and vectors and to methods of synthesizing such in vitro and in vivo, and to methods of using such to regulate gene expression," the patent application's abstract states.

Title: Detecting RNAi Using SELDI Spectrometry

Number: 20060063161

Filed: Sept.22, 2004

Lead Inventor: Reddy Gurucharan, Ciphergen Biosystems

The invention "relates to the fields of protein expression and molecular biology. In particular, the present invention includes methods for monitoring the levels of polypeptide inhibition caused by inhibitory nucleic acids," the patent application's abstract states.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.